Main Article Content

Abstract

A validated HPLC method was developed for the determination of Melphan (MPA) in pharmaceutical formulation. LC 20AT pump and UV-Visible detector with flexible wavelength programme and Rheodyne injector are used in this present problem. Phenomenex Synergi C18, 250 mm × 4.6 mm, 4µm or equivalent is used for this chromatography analysis. Column used in this measurement is Phenomenex Synergi C18,250mm×4.6mm,4µm or equivalent. Specificity (stressed condition) is confirmed by no co-elution of diluent peaks, Blank as diluent, excipients peaks, Monohydroxy MPA, Dihydroxy MPA, Isopropyl ester and dimer impurity were not interfere with MPA Peak along with each other. Obtained results are 1.2 and 270103 respectively. The method developed is simple and is better than the methods reported in the literature. With the help of different studies, therefore, we recommend pursuing an induction regimen of up to six cycles in all patients to postpone treatment with high-dose MPA. By using various studies, we recommend pursuing an induction regimen of up to six cycles in all patients to postpone treatment with high-dose MPA for SARS-CoV-2.

Keywords

RP-HPLC Refractive index detector MPA SARS-CoV-2 USP reference

Article Details

How to Cite
Vijayalakshmi Kancharla, Kumar Abbaraju V D N, Andrews B S A, Nagaraju Dasari, & Nagu Korupolu. (2020). Melphan As Anticancer And New Insights Of Drug As Parenteral Dosage Form Against SARS-CoV-2 By Using Development And Validation. International Journal of Research in Pharmaceutical Sciences, 11(SPL1), 1437-1446. https://doi.org/10.26452/ijrps.v11iSPL1.3686